SME Times is powered by   
Search News
Just in:   • Adani Group to invest Rs 57,575 crore in Odisha  • 'Dollar Distancing' finally happening? Time for India to pitch Rupee as credible alternative: SBI Ecowrap  • 49% Indian startups now from tier 2, 3 cities: Jitendra Singh  • 'India ranks 3rd in global startup ecosystem & number of unicorns'  • LinkedIn lays off entire global events marketing team: Report 
Last updated: 28 Feb, 2015  

Acceliant Announces its Partnership With Lupin Pharmaceuticals

PR Newswire | 25 Feb, 2015
BANGALORE: Acceliant, a global technology provider of advanced clinical trial data management solutions, partners with pharma major Lupin Limited (Lupin). Lupin would leverage Acceliant's clinical trial platform for its clinical research and trials across Lupin Research programs. Acceliant platforms ensure smooth execution of clinical data management activities such as database design, UAT and various report formats for business intelligence. It gives a client partner like Lupin a collaborative environment that brings global research teams to work within a single shared environment.

Ven Thangaraj, CTO of Acceliant said on this partnership: "We are proud to partner with Lupin. This is an excellent platform for us to showcase our eClinical suite of products that deliver end-to-end clinical trial data management solutions. Together, we hope to raise the level of clinical trial efficiency."

Speaking on the partnership, Santosh N. Nagaraj, Sales Head, Acceliant, commented: "Our collaboration with Lupin strengthens our clientele base and helps us to differentiate ourselves in a highly competitive market. We are very happy to partner with one of the top-branded pharmaceutical companies in India and look forward to a long-term association."

Commenting on the partnership, Ravishekar Kasibhatta, Vice-President, Lupin said - "Acceliant proved to be our partner of choice given its excellent track record and competency in clinical trial solutions, and are a part of multiple measures that we are taking to ensure 'Quality-by-design' and ensure clinical trial excellence. Acceliant's eClinical suite will go a long way in helping us to cost-effectively streamline and expedite our clinical trial processes."

About Lupin Limited

Lupin is an innovation-led transnational pharmaceutical company developing and producing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing top 5 generic pharmaceuticals player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also amongst the top 10 generic pharmaceutical players in Japan and South Africa (IMS). For the financial year ended March 2014, Lupin's consolidated turnover and Profit after Tax were Rs. 110,866 million (USD 1.83 billion) and Rs. 18,364 million (USD 304 million) respectively. Please visit for more information.

CIN: L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098.

About Acceliant

Acceliant is the medical industry technology division of Trianz, a global technology services and solutions company. A pioneer in the EDC industry, Acceliant has been providing solutions in the clinical trial management space since 1999. The company caters to the needs of the pharmaceutical, biotechnology, medical device, CRO, and non-profit drug research industries. Acceliant has helped facilitate clinical data management in hundreds of trials worldwide encompassing dozens of therapeutic areas for global giants as well as emerging healthcare innovators.

For more information, please contact:
Prashant Bhavaraju

SOURCE Acceliant

Print the Page Add to Favorite
Share this on :

Please comment on this story:
Subject :
(Maximum 1500 characters)  Characters left 1500
Your name:

  Customs Exchange Rates
Currency Import Export
US Dollar
UK Pound
Japanese Yen 58.85 56.85
As on 13 Aug, 2022
  Daily Poll
COVID-19 has directly affected your business
 Can't say
  Commented Stories
» GIC Re's revenue from obligatory cession threatened(1)
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter